We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No more baby steps

12 April 2007 By Una Galani

The Swiss drugs group found a generous buyer for this slow growth business. Nestle is paying $5.5bn, a hefty 2.8 times sales. The sale will push the Novartis cash pile up to $15bn. Big share buybacks might make sense, but acquisitions may feel more grownup.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)